
    
      Complying with requirements of the approval letter of clinical trial issued by SFDA (Approval
      Letter No.: 2006L01017), Hualan conducted phase I clinical trial of Group ACYW135
      Meningococcal Polysaccharide Vaccine. The safety end points were the presence of any
      systemic, local and adverse reaction.
    
  